- Home
- KNSA vs LZB Comparison
KNSA vs LZB Comparison
Compare KNSA & LZB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- LZB
- Stock Information
- Founded
- KNSA 2015
- LZB 1927
- Country
- KNSA United Kingdom
- LZB United States
- Employees
- KNSA N/A
- LZB N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- LZB Home Furnishings
- Sector
- KNSA Health Care
- LZB Consumer Discretionary
- Exchange
- KNSA Nasdaq
- LZB Nasdaq
- Market Cap
- KNSA 1.9B
- LZB 1.6B
- IPO Year
- KNSA 2018
- LZB N/A
- Fundamental
- Price
- KNSA $27.36
- LZB $41.97
- Analyst Decision
- KNSA Strong Buy
- LZB Buy
- Analyst Count
- KNSA 5
- LZB 2
- Target Price
- KNSA $38.80
- LZB $46.00
- AVG Volume (30 Days)
- KNSA 474.9K
- LZB 322.4K
- Earning Date
- KNSA 07-22-2025
- LZB 06-16-2025
- Dividend Yield
- KNSA N/A
- LZB 2.10%
- EPS Growth
- KNSA N/A
- LZB 7.87
- EPS
- KNSA N/A
- LZB 2.91
- Revenue
- KNSA $481,166,000.00
- LZB $2,091,871,000.00
- Revenue This Year
- KNSA $37.21
- LZB $3.42
- Revenue Next Year
- KNSA $5.32
- LZB $3.50
- P/E Ratio
- KNSA N/A
- LZB $14.37
- Revenue Growth
- KNSA 59.45
- LZB 1.80
- 52 Week Low
- KNSA $17.38
- LZB $33.34
- 52 Week High
- KNSA $28.56
- LZB $48.31
- Technical
- Relative Strength Index (RSI)
- KNSA 62.48
- LZB 49.38
- Support Level
- KNSA $26.28
- LZB $41.38
- Resistance Level
- KNSA $27.90
- LZB $43.27
- Average True Range (ATR)
- KNSA 0.99
- LZB 0.78
- MACD
- KNSA -0.07
- LZB -0.24
- Stochastic Oscillator
- KNSA 82.30
- LZB 8.68
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About LZB La-Z-Boy Incorporated
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; and Retail, which sells upholstered and case goods furniture to the end consumer. The majority of the company's revenue is derived from its Wholesale segment.